AACR – Genprex

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

March 6, 2024Kalyn Dabbs Acclaim 2 Press Releases

Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer

Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 4, 2023Kalyn Dabbs Acclaim 2 Press Releases

Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®

Designed and Secured by Barsec